Chinese Journal of New Drugs is an academic journal in the field of pharmaceutical sciences, which is administrated by National Medical Products Administration, jointly sponsored by China Medical Science Press, China National Pharmaceutical Group Corporation, and Chinese Pharmaceutical Association (CPA). It was founded since 1992, and currently a semimonthly journal publishing 24 issues per year. The journal is a member of official journals of CPA, and is included in Core Journal of China , The Key Magazine of China Technology（CSTPCD）, the source journals of China Science Citation Database(CSCD). In the years of 2008, 2014 and 2017, it was rated as one of the "Top Articles from Outstanding S&T journals of China". In 2009, the journal was funded by the China Association for Science and Technology's Top Scientific and Technological Journal Project (Category B). In 2015, it was rated as one of the "Top 100 Scientific and Technological Journals" by Nation Radio and Television Administration, National Press and Publication Administration.
This journal focuses on the new drugs independently developed by China, and tracks the frontiers of new drug research and development in the world. We also report the latest advancement of new drug development, research and application in China, promote the national policy of new drug regulation and review, follow the new progress in the fields of chemical drugs, traditional Chinese medicine and biological medicine, and introduce marketed new drugs in the world. This journal has become one of the most important academic platforms for international communication in the field of new drug development and clinical application in China.
The editorial board and academic consultant team of the journal are highly acknowledged in pharmaceutical community in China and abroad. The Editor-in-Chief is Prof. Chen Kaixian. The international editorial board is composed of 130 acknowledged experts and academic leaders engaged in basic and clinical research of pharmaceutical sciences, among which 18 are academicians.
The columns of the journal include New Drug Review and Forum, Special Tour to Major New Drug Creation, New Drug Registration and Review, Bio-pharmaceutical Frontier, Review, Clinical Research, Experimental Research, Drug Safety and Rational Application, etc. The journal, with the features of authority, cutting-edge, academic, innovation, timely and practical, has received the highest level of concern from the majority of medical workers. The audience has spread to over 30 countries and regions in hospitals, colleges and universities, research and development institutions, pharmaceutical enterprises, and drug supervision departments, etc. The Chinese Journal of New Drugs emphasizes quality for survival and reputation for development. Since its foundation, the journal has continuously expanded its influence in China and abroad in the past 30 years. It ranks the 4th in the category of pharmaceutical journals in PKU Core Journal of China Catalog (core edition) .
Awards and Index
In 2001, selected as one of the "double-effect" journals of the Chinese periodical array of the National Press and Publication Administration.
In 2002, included in Chemical Abstracts (CA) of the US.
In 2004, 2006, and 2008, three papers selected for Excellent Academic Paper Award by the Chinese Association for Science and Technology
In 2008, indexed in Research Center for Chinese Science Evaluation(RCCSE).
In 2008, included in CSTPCD.
In 2009, included in EmBase.
In 2009, included in the SCOPUS, the Netherlands.
Since 2011, included in CSCD.
In 2012, included in the core journals of pharmacyin the "Overview of the Key Items of Chinese Core Journals" (Core Journal of China) .
In 2014, rated again as one of the "China's Top Scientific and Technological Journals".
In 2015, selected as one of the "Top 100 Scientific and Technological Periodicals" of the State Administration of Press, Publication, Radio, Film and Television.
In 2017, selected as the "4th China Quality Science and Technology Journal".
In 2018, selected as one of the core journals of pharmacy in the 2017 edition of the "Overview of Chinese Core Journals".
Since 2019, included again in the database of China's core journals (selection).
In 2023, selected as one of the core journals of pharmacy in the 2020 edition of "Overview of Key Chinese Core Journals".
